Edwards Lifesciences (NYSE:EW) Raised to "Hold" at Dbs Bank

Edwards Lifesciences (NYSE:EW - Get Free Report) was upgraded by equities researchers at Dbs Bank to a "hold" rating in a research note issued to investors on Monday,Zacks.com reports.

Several other analysts also recently issued reports on the company. Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Citigroup restated a "buy" rating and issued a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Evercore ISI lowered their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. Finally, Truist Financial lowered their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Stock Down 0.3%

Shares of EW stock traded down $0.21 during trading hours on Monday, reaching $77.56. The company had a trading volume of 2,633,909 shares, compared to its average volume of 5,219,133. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $95.25. The company has a market capitalization of $45.50 billion, a P/E ratio of 11.13, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The stock's fifty day simple moving average is $73.98 and its 200 day simple moving average is $72.78.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.66 earnings per share. As a group, sell-side analysts expect that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the transaction, the chief financial officer now owns 30,387 shares of the company's stock, valued at $2,153,526.69. This represents a 27.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the completion of the sale, the vice president now owns 50,356 shares of the company's stock, valued at approximately $3,897,554.40. This represents a 4.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,012 shares of company stock valued at $4,224,717 in the last 90 days. 1.29% of the stock is owned by company insiders.

Institutional Trading of Edwards Lifesciences

A number of large investors have recently made changes to their positions in EW. Crowley Wealth Management Inc. bought a new position in Edwards Lifesciences during the 4th quarter worth about $26,000. Vega Investment Solutions bought a new position in Edwards Lifesciences during the 4th quarter worth about $27,000. Quantbot Technologies LP bought a new position in Edwards Lifesciences during the 1st quarter worth about $26,000. SouthState Corp bought a new position in Edwards Lifesciences during the 1st quarter worth about $27,000. Finally, Rossby Financial LCC bought a new position in Edwards Lifesciences during the 1st quarter worth about $29,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.